Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Capecitabine vs XELODA in Cancer Patients
NCT03435666Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2018
- Primary completion
- Oct 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Phase 1, randomised, open-label trial of capecitabine in colon cancer and breast cancer (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Timepoint. Status: unknown.
02
Drugs
capecitabine
03
Conditions
colon cancerbreast cancer
Beyond the preview
Go deeper on NCT03435666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435666.